Nancy U. Lin

41.9k total citations · 12 hit papers
375 papers, 17.2k citations indexed

About

Nancy U. Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Nancy U. Lin has authored 375 papers receiving a total of 17.2k indexed citations (citations by other indexed papers that have themselves been cited), including 265 papers in Oncology, 212 papers in Pulmonary and Respiratory Medicine and 137 papers in Cancer Research. Recurrent topics in Nancy U. Lin's work include Brain Metastases and Treatment (118 papers), HER2/EGFR in Cancer Research (101 papers) and Cancer Treatment and Pharmacology (96 papers). Nancy U. Lin is often cited by papers focused on Brain Metastases and Treatment (118 papers), HER2/EGFR in Cancer Research (101 papers) and Cancer Treatment and Pharmacology (96 papers). Nancy U. Lin collaborates with scholars based in United States, Italy and France. Nancy U. Lin's co-authors include Eric P. Winer, Ana C. Garrido-Castro, Kornélia Polyák, Jennifer R. Bellon, Lalitha Shankar, Janet Dancey, Elisabeth G.E. de Vries, F. Stephen Hodi, Lesley Seymour and Sumithra J. Mandrekar and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Nature Genetics.

In The Last Decade

Nancy U. Lin

350 papers receiving 17.0k citations

Hit Papers

iRECIST: guidelines for response c... 2004 2026 2011 2018 2017 2016 2019 2008 2004 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
    2017 1.5k citations Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology profile →
  2. RECIST 1.1—Update and clarification: From the RECIST committee
    2016 1.2k citations Lawrence H. Schwartz, Saskia Litière et al. profile →
  3. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
    2019 964 citations Nancy U. Lin et al. profile →
  4. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer
    2008 546 citations Nancy U. Lin, Jessica Sohl et al. Cancer profile →
  5. CNS Metastases in Breast Cancer
    2004 543 citations Nancy U. Lin, Eric P. Winer et al. Journal of Clinical Oncology profile →
  6. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
    2017 500 citations Nancy U. Lin et al. Neuro-Oncology profile →
  7. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
    2012 475 citations Nancy U. Lin, Melissa E. Hughes et al. Cancer profile →
  8. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer
    2016 364 citations Nadine Tung, Nancy U. Lin et al. Journal of Clinical Oncology profile →
  9. Global challenges and policy solutions in breast cancer control
    2022 172 citations Nancy U. Lin, Michael J. Hassett et al. Cancer Treatment Reviews profile →
  10. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
    2022 163 citations Melissa E. Hughes, Thomas M. Roberts et al. Nature Communications profile →
  11. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
    2022 147 citations Qingchun Jin, Nabihah Tayob et al. profile →
  12. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
    2022 116 citations Carey K. Anders, Ian E. Krop et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nancy U. Lin United States 63 11.2k 7.7k 4.0k 3.5k 2.3k 375 17.2k
Aditya Bardia United States 58 10.9k 1.0× 5.4k 0.7× 5.0k 1.2× 4.0k 1.1× 1.8k 0.8× 481 16.1k
Véronique Dièras France 63 18.5k 1.7× 9.5k 1.2× 6.3k 1.6× 4.3k 1.3× 3.1k 1.3× 354 23.3k
Sara M. Tolaney United States 54 11.6k 1.0× 5.3k 0.7× 3.7k 0.9× 2.8k 0.8× 2.0k 0.9× 502 14.8k
Igor Bondarenko United States 54 13.3k 1.2× 9.0k 1.2× 3.6k 0.9× 3.3k 0.9× 846 0.4× 317 17.7k
Mario Campone France 66 15.3k 1.4× 9.0k 1.2× 7.1k 1.8× 7.6k 2.2× 3.2k 1.4× 538 23.9k
Hiroji Iwata Japan 63 16.7k 1.5× 9.6k 1.2× 7.1k 1.7× 4.8k 1.4× 1.9k 0.8× 520 23.8k
Adam Brufsky United States 69 10.0k 0.9× 5.3k 0.7× 4.5k 1.1× 3.2k 0.9× 1.8k 0.8× 505 16.0k
Jungsil Ro South Korea 52 7.9k 0.7× 5.3k 0.7× 3.6k 0.9× 3.5k 1.0× 1.4k 0.6× 189 13.3k
Angelo Di Leo Italy 62 9.9k 0.9× 4.5k 0.6× 5.2k 1.3× 4.1k 1.2× 1.7k 0.7× 313 14.4k
John Crown Ireland 71 13.0k 1.2× 4.8k 0.6× 6.0k 1.5× 7.4k 2.1× 2.4k 1.0× 416 20.1k

Countries citing papers authored by Nancy U. Lin

Since Specialization
Citations

This map shows the geographic impact of Nancy U. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy U. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy U. Lin more than expected).

Fields of papers citing papers by Nancy U. Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy U. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy U. Lin. The network helps show where Nancy U. Lin may publish in the future.

Co-authorship network of co-authors of Nancy U. Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy U. Lin. A scholar is included among the top collaborators of Nancy U. Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy U. Lin. Nancy U. Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leone, José Pablo, Julieta Leone, Carlos Vallejo, et al.. (2025). Factors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer. Clinical Breast Cancer. 25(4). 344–353.
2.
Jovanović, Bojana, S. Church, Khrystyna North, et al.. (2024). Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies. Clinical Cancer Research. 30(20). 4768–4779. 3 indexed citations
3.
Zañudo, Jorge Gómez Tejeda, Romualdo Barroso‐Sousa, Esha Jain, et al.. (2024). Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature Communications. 15(1). 2446–2446. 15 indexed citations
4.
Rader, Ryan K., Carey K. Anders, Nancy U. Lin, & Sarah Sammons. (2023). Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases. Current Treatment Options in Oncology. 24(6). 611–627. 4 indexed citations
5.
Xia, Daniel, Frank C. Kuo, Melissa E. Hughes, et al.. (2023). HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer. American Journal of Clinical Pathology. 161(5). 436–442. 5 indexed citations
6.
Müller, Volkmar, Rupert Bartsch, Nancy U. Lin, et al.. (2023). Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. Cancer Treatment Reviews. 115. 102527–102527. 13 indexed citations
7.
Lipsyc-Sharf, Marla, Elza C. de Bruin, Robert McEwen, et al.. (2022). Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 40(22). 2408–2419. 85 indexed citations
8.
Cheung, Yee-Ming Melody, Melissa E. Hughes, Janet Files, et al.. (2022). The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer. The Journal of Clinical Endocrinology & Metabolism. 107(9). 2511–2521. 8 indexed citations
9.
Winer, Eric P., et al.. (2021). How we treat HER2-positive brain metastases. ESMO Open. 6(5). 100256–100256. 29 indexed citations
10.
11.
Hulsbergen, Alexander, An Claes, Vasileios K. Kavouridis, et al.. (2020). Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro-Oncology. 22(8). 1173–1181. 75 indexed citations
12.
Poorvu, Philip D., Inês Vaz-Luís, Rachel A. Freedman, et al.. (2018). Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Research and Treatment. 168(3). 727–737. 13 indexed citations
13.
Ferreira, Arlindo R., Vasco Sanchez Rodrigues, Ana Miranda, et al.. (2017). Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study. The Breast. 37. 107–113. 7 indexed citations
14.
Seymour, Lesley, Jan Bogaerts, Andrea Perrone, et al.. (2017). iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 18(3). e143–e152. 1528 indexed citations breakdown →
15.
16.
Cheng, Hailing, Carolynn E. Ohlson, Elaine Xu, et al.. (2015). PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 35(23). 2961–2970. 32 indexed citations
17.
Olson, Erik M., Mahmoud Abdel‐Rasoul, J Malý, et al.. (2013). Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Annals of Oncology. 24(6). 1526–1533. 104 indexed citations
18.
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aditya Bardia Breakdown of academic impact, for papers by Véronique Dièras Breakdown of academic impact, for papers by Sara M. Tolaney Breakdown of academic impact, for papers by Igor Bondarenko Breakdown of academic impact, for papers by Mario Campone Breakdown of academic impact, for papers by Hiroji Iwata Breakdown of academic impact, for papers by Adam Brufsky Breakdown of academic impact, for papers by Jungsil Ro Breakdown of academic impact, for papers by Angelo Di Leo Breakdown of academic impact, for papers by John Crown
Rankless by CCL
2026